
Curis (CRIS) Stock Forecast & Price Target
Curis (CRIS) Analyst Ratings
Bulls say
Curis is supported primarily by the strengthening registrational PCNSL data, where emavusertib plus ibrutinib delivered a 26% ORR across all 39 BTKi-experienced patients and 33% in 30 evaluable patients, while the BTKi-naïve cohort reached 86% ORR on an all-patients basis and 100% in five of five evaluable patients. The company also has a credible regulatory path, with prior FDA and EMA feedback supporting potential accelerated approval in the U.S. and Conditional Marketing Authorization in Europe, alongside management’s plan for full enrollment by 2027 and an NDA filing anticipated in 2028. Although Curis ended 3Q26 with only $5.0 million in cash, the subsequent $7.5 million private placement funds operations into 1Q27, and the expanding CLL program plus broader NHL optionality provide additional upside.
Bears say
Curis is facing a strained fundamental outlook because the increase in fully diluted share count after the October 2026 private placement and warrant repricing materially dilutes value, while management still needs substantial additional capital to fund development. Its lead PCNSL asset has shown only a 26% all-patients response rate in the BTKi-experienced cohort as of July 1, 2026, with a cohort that expanded 50% while the response rate held flat, and the more meaningful full-approval path now requires a randomized confirmatory study to be underway before filing. In addition, AML/MDS assumptions were weakened by lowering probability of success to 10% from 15% and pushing projected launch to 2033 from 2032, reinforcing concerns that clinical execution, financing needs, and dilution could pressure the stock.
This aggregate rating is based on analysts' research of Curis and is not a guaranteed prediction by Public.com or investment advice.
Curis (CRIS) Analyst Forecast & Price Prediction
Start investing in Curis (CRIS)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Curis (CRIS) Forecast
Curis (CRIS) Analyst Forecast & Price Prediction
Start investing in Curis (CRIS)
Order type
Buy in
Order amount
Est. shares
0 shares